{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-100433","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.387170+00:00","generated_at":"2026-05-23T05:02:50.625097+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esther Rajavelu named Spero CEO effective May 2; former CEO Sath Shukla departs","bullets":["Esther Rajavelu appointed President and CEO effective May 2, 2025; nominated for board election at annual meeting.","Rajavelu continues as CFO and Treasurer; base salary $620K, target bonus 50%, 185,000 RSUs vesting over 4 years.","Former CEO Sath Shukla mutually separates; receives salary continuation of $615,825, cash bonus $307,913, and retention bonus $452,813.","Company expects update on PIVOT-PO Phase 3 trial for tebipenem HBr this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-100433","json":"https://secwatch.observer/filing/0001193125-25-100433.json","markdown":"https://secwatch.observer/filing/0001193125-25-100433.md","text":"https://secwatch.observer/filing/0001193125-25-100433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525100433/0001193125-25-100433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525100433/d807820d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:02:50.625097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"858adc3ff3","claim":"Esther Rajavelu was appointed as President and Chief Executive Officer at Spero Therapeutics, Inc..","evidence_excerpt":"On April 28, 2025, Spero Therapeutics, Inc. (the “Company”) announced that effective as of May 2, 2025 (the “Effective Date”), Esther Rajavelu will serve as the Company’s President and Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525100433/0001193125-25-100433-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}